Scarica l'app Stockscreener
6.85
1.64%
0.15
Precedente Chiudi:
$6.70
Aprire:
$6.72
Volume 24 ore:
93,283
Relative Volume:
0.27
Capitalizzazione di mercato:
$265.92M
Reddito:
$25.42M
Utile/perdita netta:
$-143.75M
Rapporto P/E:
-1.9736
EPS:
-3.4709
Flusso di cassa netto:
$-129.55M
1 W Prestazione:
+12.75%
1M Prestazione:
-47.45%
6M Prestazione:
-32.44%
1 anno Prestazione:
-11.56%
Intervallo 1D:
$6.60
$6.86
Intervallo di 1 settimana:
$5.93
$6.86
Portata 52W:
$4.93
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Nome
Entrada Therapeutics Inc
Settore
Industria
Telefono
857-305-1825
Indirizzo
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
6.85 | 260.10M | 25.42M | -143.75M | -129.55M | -3.4709 |
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.28 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
827.11 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.81 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.19 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-11 | Iniziato | Guggenheim | Buy |
| 2026-01-28 | Iniziato | Oppenheimer | Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-01-05 | Iniziato | Oppenheimer | Outperform |
| 2023-04-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
Behavioral Patterns of TRDA and Institutional Flows - Stock Traders Daily
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Entrada Therapeutics clinical trial data sparks brutal stock selloffhere's why - MSN
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TRDA - Finviz
Insider Move at Entrada Therapeutics Sparks Fresh Investor Interest - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Entrada Thera - The National Law Review
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock By Investing.com - Investing.com Australia
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock - Investing.com
Entrada Therapeutics (TRDA) director’s trust buys 5,000 common shares - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutic - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
User - The Chronicle-Journal
Entrada Therapeutics Reports Positive Phase 1/2 Results for ENTR-601-44 in Duchenne Muscular Dystrophy, Highlighting Best-in-Class Potential and $5B U.S. Market Opportunity 679 - Minichart
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress - TipRanks
Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026 - TradingView
Entrada Therapeutics (TRDA) furnishes updated corporate presentation to investors - Stock Titan
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review
INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC - GlobeNewswire
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Scott Coop
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
(TRDA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Entrada Therapeutics faces investigation after drug trial results disappoint, stock plunges 57%. - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc.TRDA - PR Newswire
Entrada Therapeutics, Inc. Common Stock (TRDA) Stock Price Today & Analysis - Gotrade
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
HC Wainwright Has Positive Estimate for TRDA Q2 Earnings - MarketBeat
TradingKey - TradingKey
Investors in Entrada Therapeutics urged to join probe after stock drops on clinical trial results - Pluang
Entrada Therapeutics, Inc. Shareholders Are Encouraged to - GlobeNewswire
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
MSN Money - MSN
Transcript : Entrada Therapeutics, Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile - Barchart.com
Entrada Therapeutics, Inc.Common Stock (NQ: TRDA - FinancialContent
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock SelloffHere's Why - Sahm
Entrada Therapeutics Cut to Neutral From Buy by HC Wainwright & Co. - Moomoo
This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga
H.C. Wainwright Downgrades Entrada Therapeutics(TRDA.US) to Hold Rating - Moomoo
Entrada’s stock drops as DMD drug’s efficacy falls short - Yahoo Finance
Entrada Therapeutics Declines on Duchenne Muscular Dystrophy Study Data -- Update - Moomoo
Entrada’s ENTR-601-44 Shows Efficacy, But Dystrophin Raises Questions - Citeline News & Insights
Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Entrada sinks on mixed DMD data with ENTR-601-44 - BioWorld News
Entrada Therapeutics Announces Positive Topline Results from Coho - The National Law Review
Entrada plunges on trial data for Duchenne drug (TRDA:NASDAQ) - Seeking Alpha
Entrada Therapeutics Inc Azioni (TRDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.67%
1.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):